AXDEV Group Inc.

This October, we stand in solidarity with the millions of women, men, and families impacted by breast cancer. Last month, at #ASCOQLTY24, AXDEV’s team presented the real-world evidence of a project entitled, “Optimizing Patient Access to CDK 4/6 Inhibitors in the Arsenal Against Metastatic Breast Cancer”. We believe in the power of early detection, support, and education to make a difference. Many thanks to our collaborators Antidote Education Company and Pfizer for the independent medical education grant. Together we can help, empower survivors, and honour the strength of those who have fought and continue to fight. Let’s turn awareness into action. #BreastCancerAwareness #HopeForACure #StrongerTogether #ThinkPink #EarlyDetectionSavesLives

Please join a great faculty and our CEO, Suzanne Murray, this Thursday, September 12, 2024 at 12:00 PM (EDT) for the Alliance for CEhp - Alliance Learn “Showcasing Success: Disseminating Your Work Matters” Live Web Event This webinar is designed for a wide audience whether you are beginning to think about dissemination or if you have successfully submitted to a society conference or peer-reviewed journal. The panel will actively engage with the audience, offering guidance and practical tips to address your questions on measuring impact and effectively disseminating your work through various channels, including social media, professional societies, and journals. https://lnkd.in/epGAAEcw

The AXDEV team is proud to share that, in collaboration with our co-authors and collaborators, Melissa Kelly (ASCP), Kellie Beumer (ASCP), and Joseph Kim (QSynthesis), our poster / abstract entitled “Impact of a PD-L1 Learning Collaborative: outcomes from a mixed-methods evaluation”, received the AWARD for “Best Test Utilization Poster“ at the annual conference of the American Society for Clinical Pathology (ASCP) . This project was supported by an Independant Educational Grant from Merck. https://lnkd.in/eaamuqV7

AXDEV is thrilled to share our latest publication, "Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States." now published in BMC Cancer. This article was a result of a Needs Assessment project financially supported by educational research funds from Eli Lilly & Company. #research #publication #healthcare https://lnkd.in/eXfM7JW8

📢 As I conclude my first training program in the USA, I want to express my heartfelt gratitude to Dr. Manmeet Ahluwalia, MD, MBA, FASCO, for his generosity in offering me the opportunity to work closely with him at the Miami Cancer Institute, Baptist Health BAPTIST HEALTH SOUTH FLORIDA FOUNDATION INC. This experience not only allowed me to acclimate to a new city and country but also provided an unparalleled start to my training journey. ✨ Over the past year, I have had the privilege of delving into both the academic and industrial facets of neurooncology under Dr. Ahluwalia's guidance. His mentorship enabled me to work on groundbreaking projects involving artificial intelligence in brain cancer, for which he secured The National Institutes of Health R01 grants. ✨ Additionally, I was fortunate to collaborate with esteemed industry partners such as Cellworks, Caris Life Sciences, AXDEV Group Inc., Eli Lilly and Company, Bayer, Guardant Health, and Natera to name a few. ✨ I am also grateful for the opportunity to present my works at the American Academy of Neurology and the American Society of Clinical Oncology (ASCO) in Denver and Chicago, experiences made possible through the generous support of the BAPTIST HEALTH SOUTH FLORIDA FOUNDATION INC. Thank you, Dr. Ahluwalia Manmeet Ahluwalia, MD, MBA, FASCO, and the entire team Amy K. Starosciak, Ph.D., Zhijian Chen Vivek Podder, MBBS, Maggie Varena for an incredible year of learning and growth. OncoDaily Targeted Oncology

AXDEV is honored to be in the top 4 Blue Ribbon abstract finalists for the ASCP 2024 Congress. https://lnkd.in/eeGASxtH

This rare disease FOP is horrific for patients and challenging for healthcare professionals. We are pleased to have the opportunity to conduct important projects and research in this field!